Patents Examined by S. Nolan
-
Patent number: 5139944Abstract: The collagenase is like tissue collagenases in that it cleaves collagen at a single site. The collagenase which has a molecular weight of about 50 k daltons, specifically inhibits collagen-induced platelet aggregation, with substantially no effect on platelet count or size, and may be used alone or together with another platelet aggregation inhibitor. The latter may also be a leech-derived biochemical, such as an apyrase, or an inhibitor of the release of platelet aggregation factor by leucocytes.Type: GrantFiled: January 30, 1991Date of Patent: August 18, 1992Assignees: Biophram (UK) Limited, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Roy T. Sawyer, Meir Rigbi, Haim Levy, Fuad Iraqi
-
Patent number: 5104806Abstract: An analog of porcine growth hormone, is disclosed which retains the diabetogenic, insulin-sparing and lipolytic properties of porcine growth hormone while being capable of improving growth in mammals.Type: GrantFiled: March 12, 1987Date of Patent: April 14, 1992Assignees: Amgen, Inc., SmithKline Beecham CorporationInventor: Lawrence M. Souza
-
Patent number: 5037743Abstract: Methods for producing heterologous proteins in a host organism whereby the proteins are processed through the secretory pathway of the host are provided. Secretion is achieved by transforming a host organism with a DNA construct comprising a transcriptional promoter operably linked to DNA sequences encoding a signal peptide, at least a portion of the BAR1 C-terminal domain capable of directing the export of heterologous proteins and a heterologous protein or polypeptide. DNA constructs and transformants are also provided wherein the DNA sequence encoding at least a portion of the C-terminal domain of BAR1 capable of directing the export of heterologous proteins further comprises a DNA sequence encoding a proteolytic cleavage site operably linked to the DNA sequence encoding a heterologous protein.Type: GrantFiled: November 14, 1988Date of Patent: August 6, 1991Assignee: ZymoGenetics, Inc.Inventors: Susan K. Welch, Vivian L. MacKay, Carli L. Yip
-
Patent number: 5026544Abstract: The present disclosure is directed to the use of combinations of a papaverine family member agent together with an interferon for the treatment of proliferative disorders such as neoplasias and hyperplasias. Disclosed are compositions and formulations which take advantage of the synergistic antiproliferative activities of these agents and the use of these compositions and formulations in the treatment of these disorders.Type: GrantFiled: February 16, 1988Date of Patent: June 25, 1991Assignee: Board of Reagents, The University of Texas SystemInventors: Thomas B. Albrecht, Thomas E. Albrecht, William R. Fleischmann
-
Patent number: 5017477Abstract: A bacterial cell transformed with a gene encoding a desired product and with an enhancing DNA sequence capable of enhancing the production of the desired product in the bacterial cell, the enhancing DNA sequence being further characterized in that it is capable of enhancing the production of an endogenous protease in a Gram-positive bacterial cell.Type: GrantFiled: October 20, 1986Date of Patent: May 21, 1991Assignee: BioTechnica International, Inc.Inventors: Alan Sloma, Rosalind C. Lee, Janice Pero
-
Patent number: 5010001Abstract: Enhanced production of B. thuringiensis delta-endotoxin is achieved by employing the naturally occurring gene where an abbreviated 3'- and 5'-non-coding flanking region is employed. Particularly, the 3'-flanking does not extend past the downstream HincII cleavage site and the 5'-flanking region does not extend past the upstream HincII cleavage site. By having abbreviated flanking regions, enhanced production of the delta-endotoxin in E. coli is obtained.Type: GrantFiled: March 28, 1985Date of Patent: April 23, 1991Assignee: Syntro CorporationInventor: Thomas J. Pollock
-
Patent number: 4970155Abstract: This invention encompasses an eukaryotic expression vector constructed from a prokaryotic plasmid by inserting into the prokaryotic plasmid a mediator sequence and a promoter/regulatory sequence with a restriction endonuclease site for inserting a gene to be expressed. The gene to be expressed is inserted into the restriction endonuclease site in the promoter/regulatory sequence and the resulting plasmid is in turn used to transform a eukaryotic cell. The gene is expressed with or without viral mediation.Type: GrantFiled: November 23, 1988Date of Patent: November 13, 1990Assignee: Abbott LaboratoriesInventor: Gregory F. Okasinski
-
Patent number: 4960877Abstract: DNA having a base sequence encoding a specified amino acid sequence of a polypeptide constituting an L-.alpha.-glycerophosphate oxidase (GPO) is disclosed. A polypeptide having the specified amino acid sequence can be produced by inserting the DNA into a plasmid, culturing a transformant produced by introducing this plasmid into a host microorganism which is selected from microorganisms belonging to Escherichia coli, Bacillus subtilis, or Saccharomyces cerevisiae. The GPO is useful for the quantitative analysis of triglyceride, glycerine, etc., and the determination of lipase activity, when used in combination with other enzymes such as lipase, glycerol kinase, or the like, or with an ATP reagent.Type: GrantFiled: December 12, 1988Date of Patent: October 2, 1990Assignee: Toyo Jozo Co., Ltd.Inventors: Hitoshi Sagai, Keiko Nogata, Mamoru Takahashi
-
Patent number: 4959323Abstract: In accordance with the present invention, recombinant plasmids are described which, when inserted into microbial hosts, direct the synthesis of proteins in which preS polypeptides found on the surface of human hepatitis B virus are fused to the enzyme .beta.-galactosidase. The recombinant plasmids are produced by inserting DNA sequences encoding the preS polypeptides into the lacZ gene, which codes for E. coli .beta.-galactosidase, carried by the plasmids. Large amounts of the preS-.beta.-galactosidase fusion proteins can be isolated from microbial cultures carrying the recombinant plasmids. Antigenic determinants of fusion protein so produced are recognized by antibodies to the preS determinants of native hepatitis B virus. The .beta.-galactosidase activity of such fusion protein is detected by a suitable chromogenic or fluorogenic substrate. PreS-.beta.Type: GrantFiled: November 4, 1985Date of Patent: September 25, 1990Assignee: Mt. Sinai School of Medicine of the City University of New YorkInventors: George Acs, Judith K. Christman, Peter Price, Wolf Offensperger, Silke Wahl
-
Patent number: 4933286Abstract: An isoenzyme from tomato, acid phosphatase-1 isoenzyme (Apase-1.sup.1), has ben purified to homogeneity and is subjected to amino acid sequencing and used to prepare anti-Apase-1 antibodies. The amino acid sequence permits design of probes to recover Apase-1.sup.1 -encoding cDNA; the antibodies are also useful for this purpose. The cDNA is useful to recover the genomic DNA encoding Apase-1.sup.1, which can then be used in walking or jumping techniques to recover the genomic DNA which confers nematode resistance, since this DNA resides immediately adjacent to the Apase-1.sup.1 gene on chromosome 6 of Lycopersicon esculentum.Type: GrantFiled: March 30, 1987Date of Patent: June 12, 1990Assignee: Plant Cell Research Institute, Inc.Inventors: Elizabeth M. Paul, Valerie M. Williamson, Jack L. Erion, Candace G. Poutre